<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-83337</identifier>
<setSpec>0300-2896</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Organizing Pneumonia Associated with the Use of Trastuzumab</dc:title>
<dc:description xml:lang="en">Organizing pneumonia is a clinical and histological condition in which the onset is usually subacute with respiratory symptoms and pulmonary infiltrates. It may be unknown origin (cryptogenic) or associated with other illnesses, infectious diseases or drugs. We present a 60 year-old female patient with a previous history of breast cancer, who was being treated with trastuzumab, an antiHER2 monoclonal antibody. She was diagnosed with casual pulmonary infiltrates that had histological changes compatible with organizing pneumonia. The pulmonary infiltrates disappeared on withdrawing trastuzumab treatment. Due to the increasing use of biological therapies in different medical areas, we believe it is of interest to report this pulmonary involvement attributed to the monoclonal antibody trastuzumab(AU)</dc:description>
<dc:creator>Servitja-Tormo, Sònia</dc:creator>
<dc:creator>Curull, Víctor</dc:creator>
<dc:creator>Pijuan, Lara</dc:creator>
<dc:creator>Maiques-Llácer, José María</dc:creator>
<dc:creator>Taus-García, Álvaro</dc:creator>
<dc:creator>Sánchez-Font, Albert</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La neumonía organizada es una entidad clinicohistológica que suele manifestarse de forma subaguda con clínica respiratoria e infiltrados pulmonares. Puede ser de causa desconocida (criptogenética) o estar asociada a distintas enfermedades, infecciones o fármacos. Presentamos el caso de una paciente de 60 años con antecedentes de una neoplasia de mama, motivo por el cual seguía tratamiento con trastuzumab, un anticuerpo monoclonal anti-HER2, a quien se detectó de forma casual un infiltrado pulmonar, cuya biopsia transbronquial fue diagnóstica de neumonía organizada. Tras la retirada del fármaco desapareció el infiltrado pulmonar. Debido a la creciente utilización de la terapia biológica en diferentes campos de la clínica, nos parece de interés comunicar esta forma de afectación pulmonar atribuible al anticuerpo monoclonal trastuzumab(AU)</dc:description>
<dc:source>Arch Bronconeumol;46(8): 442-444, ago. 2010. ilus</dc:source>
<dc:identifier>ibc-83337</dc:identifier>
<dc:title xml:lang="es">Neumonía organizada asociada a tratamiento con trastuzumab</dc:title>
<dc:subject>^d11443^s22036</dc:subject>
<dc:subject>^d974^s22020</dc:subject>
<dc:subject>^d920^s22020</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d1968^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d1716</dc:subject>
<dc:type>article</dc:type>
<dc:date>201008</dc:date>
</metadata>
</record>
</ibecs-document>
